Aiding in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by American College of Obstetricians (ACOG) guidelines) within two weeks of presentation.

• The results of the test are not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.
• The results of the test are not a stand-alone test for monitoring of hypertensive disorders of pregnancy.
• The results of the test are not intended to inform the healthcare provider whether or not to change treatment, including medication or hospitalization.

For 24 hours before specimen collection, the patient should not receive intravenous heparin.

Gold serum separator (SST) tube

 or

Red serum vial/tube, 5 mL

Immediately following collection, mix sample thoroughly by gentle inversion, 5 times

1. Allow sample to clot for a minimum of 30 minutes
2. Spin within two (2) hours of sample collection
3. Transfer 1.0mL  serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
4. Freeze

Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp)

Lavender (EDTA), 4mL

Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting

Frozen (preferred) - 6 months

Refrigerated - 24 hours

Ambient - 24 hours

Homogenous immunoassay

See report